by Silvia Prades | Oct 2, 2024 | News Articles
Last week, Dr Silvia Prades attended a conference to find out more about the latest work on rare diseases and how the medicines regulatory framework is expected to change in the coming years to facilitate research and approval of treatments for rare conditions like...
by Silvia Prades | Aug 9, 2024 | News Articles
CureDRPLA co-founders, Paul and Andrea Compton, have a son with DRPLA and their personal experiences with this devastating condition are the driving force behind CureDRPLA. Earlier this year, CureDRPLA announced that n-Lorem had an experimental treatment for DRPLA and...
by Silvia Prades | Jul 30, 2024 | News Articles
Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co., Ltd., two Japanese companies, have announced they recently co-created an antisense oligonucleotide (ASO) for DRPLA. ASOs have emerged as a promising strategy for various neurodegenerative conditions,...
by Silvia Prades | Jul 3, 2024 | News Articles
Junko Shiozawa, Advisory Board Member to CureDRPLA, has created a community of Japanese families affected by DRPLA. They offer peer support to each other and host online meetings. Since DRPLA is more common in Japan, it was important for us to create a Japanese...
by Silvia Prades | Jun 10, 2024 | News Articles
CureDRPLA has been funding research that aims to better understand DRPLA symptoms and how this condition develops over time, such as the DRPLA Natural History and Biomarkers Study. While such research projects are essential for advancing research towards clinical...
Recent Comments